Literature DB >> 29519384

Public Health Impact of the Centers for Medicare and Medicaid Services Decision on Pass-Through Add-On Payments for Drug-Coated Balloons: A Call to Action.

Mehdi H Shishehbor1, Michael R Jaff2, Joshua A Beckman3, Sanjay Misra4, Peter A Schneider5, Robert Lookstein6, Vikram S Kashyap7, Herbert D Aronow8, W Schuyler Jones9, Christopher J White10.   

Abstract

On Wednesday, November 1, 2017, the Centers for Medicare and Medicaid Services (CMS) made a public decision to end the transitional pass-through add-on payment for drug-coated balloons beginning January 1, 2018, without creating a new ambulatory payment classification rate for these devices. In this Viewpoint, the authors highlight the disconnect between the CMS's decision not to create a new ambulatory payment classification category for drug-coated balloons despite demonstrated clinical superiority. The authors believe this decision is more in line with a rigid fee-for-service payment system than a value-based system that encourages quality over quantity, and disadvantages both the elderly and the poor. They call on all who advocate for patients with peripheral artery disease to action, encouraging their engagement on CMS decisions regarding payment.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Center for Medicare and Medicaid Services; drug-coated balloons; fee-for-service; pass-through add-on payments; public health; value-based system

Mesh:

Substances:

Year:  2018        PMID: 29519384     DOI: 10.1016/j.jcin.2018.01.233

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  1 in total

1.  Is There a Real Association Between Paclitaxel Devices and Mortality? Time to Pause and Re-Evaluate What We Know About This Statistical Finding.

Authors:  Mehdi H Shishehbor; Eric A Secemsky; Ramon L Varcoe
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.